Table 2.
mRNA-LNP vaccine candidates in clinical trials.
| Sponsoring Institution | Name | Infectious disease target [strain] | mRNA encoding [administration] | Trial numbers [phase] | Status |
|---|---|---|---|---|---|
| Arcturus Therapeutics | ARCT-021 | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] |
NCT04480957 [I/II] NCT04668339 [II] NCT04728347 [II] |
Recruiting Ongoing Recruiting |
| BioNTech RNA Pharmaceuticals; Pfizer | BNT162a1; BNT162b1; BNT162b2 (branded as Comirnaty); BNT162b3; BNT162c2; BNT162-04 |
COVID-19 [SARS-CoV-2] | Spike protein; Spike receptor binding domain [i.m.] |
NCT04380701 [I/II] NCT04368728 [II/III] NCT04523571 [I] NCT04537949 [I/II] NCT04588480 [I/II] NCT04649021 [II] NCT04713553 [III] NCT04754594 [II/III] NCT04816643 [I] NCT04816669 [III] 2020-001038-36a [I/II] 2020-002641-42a [I/II/III] 2020-003267-26a [I/II] ChiCTR2000034825b [I] |
Recruiting Recruiting Ongoing Ongoing Ongoing Ongoing Recruiting Recruiting Recruiting Recruiting Ongoing Ongoing Ongoing Recruiting |
| Chulalongkorn University | ChulaCov19 | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04566276 [I] | Not yet recruiting |
| CureVac AG | CV702 | Rabies | Rabies virus glycoprotein [i.m.] | NCT03713086 [I] | Ongoing |
| CureVac AG; Coalition for Epidemic Preparedness Innovations (CEPI) | CVnCoV | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] |
NCT04449276 [I] NCT04515147 [II] NCT04674189 [III] 2020-001286-36a [I] |
Ongoing Ongoing Recruiting Ongoing |
| Daiichi Sankyo | DS-5670a | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04821674 [I/II] | Recruiting |
| GlaxoSmithKline | CoV-2 SAM | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04758962 [I] | Recruiting |
| Imperial College London | LNP-nCoVsaRNA | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | 2020-001646-20a [I] | Ongoing |
| Moderna | mRNA-1647 mRNA-1443 |
Cytomegalovirus (CMV) | CMV glycoprotein H pentamer complex [i.m.] | NCT03382405 [I] NCT04232280 [II] | Completed Recruiting |
| mRNA-1653 | Combination human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) | hMPV and PIV3 membrane fusion protein [i.m.] |
NCT03392389 [I] NCT04144348 [I] |
Completed Recruiting |
|
| VAL-506440; mRNA-1440 | Influenza A virus [H10N8] | Membrane-bound hemagglutinin 10 (H10) protein mRNA; [i.m.] | NCT03076385 [I] | Completed | |
| VAL-339851; mRNA-1851 | Influenza A virus [H7N9] | Membrane-bound hemagglutinin 7 (H7) [i.m.] | NCT03345043 [I] | Completed | |
| mRNA-1345 | Respiratory syncytial virus (RSV) | RSV prefusion F protein [i.m.] | NCT04528719 [I] | Recruiting | |
| Moderna; Biomedical Advanced Research and Development Authority | VAL-181388; mRNA-1388; mRNA-1944 |
Chikungunya virus (CHIKV) | Antigenic proteins associated with CHIKV [i.m.] Anti-CHKV monoclonal antibody [i.m.] |
NCT03325075 [I] NCT03829384 [I] |
Completed Ongoing |
| mRNA-1325; mRNA-1893 |
Zika virus | prME structural protein [i.m.] |
NCT03014089 [I] NCT04064905 [I] |
Completed Ongoing |
|
| Moderna; Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases |
mRNA-1273; mRNA-1283 |
COVID-19 [SARS-CoV-2] | Spike protein [i.m.] |
NCT04283461 [I] NCT04405076 [II] NCT04470427 [III] NCT04649151 [II/III] NCT04796896 [II/III] NCT04813796 [I] |
Ongoing Recruiting Ongoing Ongoing Recruiting Ongoing |
| National Institute of Allergy and Infectious Diseases | SAM-LNP-S | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04776317 [I] | Recruiting |
| Providence Therapeutics | PTX-COVID19-B | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04765436 [I] | Recruiting |
| Sanofi Pasteur | MRT5500 | COVID-19 [SARS-CoV-2] | Spike protein [i.m.] | NCT04798027 [I/II] | Recruiting |
| Shulan (Hangzhou) Hospital; Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region; Suzhou Abogen Biosciences; Yunnan Walvax Biotechnology | ARCoV | COVID-19 [SARS-CoV-2] | Spike receptor binding domain [i.m.] | ChiCTR2000034112b [I] | Recruiting |
a
EudraCT number.
b
Chinese Clinical Trial Registry.